The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | The challenges of treating TP53-mutated AML and MDS
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the challenges of treating patients with TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting the poor outcomes associated with these patients. Dr Sallman also comments on the need to investigate novel therapeutic strategies for these patients, and highlights agents of interest, including eprenetapopt and magrolimab. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
